What This Study Examined

SelN sits inside the sarcoplasmic reticulum of muscle cells, where it helps regulate calcium levels and protects cells from oxidative damage. When the gene encoding SelN is mutated, muscle cells lose this protection, leading to muscle weakness, spinal rigidity, and respiratory insufficiency.

This review examined how SelN normally works, what goes wrong at the cellular level without it, and what treatments are being explored.

Key Findings

Symptoms start early: Nearly 80% of affected individuals show signs of this condition—muscle weakness, poor head/trunk control, breathing difficulty—within the first two years of life.
Disease is more progressive than once thought: A recent long-term study found that even "stable" individuals often experience gradual decline in muscle and respiratory function starting in their 20s and 30s, with some losing the ability to walk.
Three interconnected problems drive disease: Loss of SelN disrupts (1) the cell's stress-response system, (2) calcium handling needed for muscle contraction, and (3) energy metabolism—all contributing to muscle damage.
Weight matters: Underweight individuals tend to keep walking longer; being overweight is linked to faster disease progression, possibly due to added cellular stress.
Promising drug candidates: A bile-acid compound called TUDCA improved muscle function in animal models by reducing cellular stress, and a related antioxidant (NAC) has already been tested with mixed results.

Why This Matters

This review reframes SELENON-RM as a condition involving faulty cellular "quality control," not just a structural muscle problem. That distinction matters because it points toward drug-based treatments that could restore healthy cell function—like TUDCA or NAC—rather than only relying on gene-replacement approaches.

It also highlights that ambulation and respiratory decline can continue into adulthood, reinforcing the value of ongoing monitoring, early ventilation support, and thoughtful weight management, even in those whose symptoms seem stable.

Help Fuel CMD Progress Now

Research like this moves forward because people choose to fund it.

Right now, Cure CMD is actively reviewing research projects to fund in 2026. Your donation today helps us invest in the most promising science, moving discoveries like this one closer to real treatments and therapies.

Donate today to help accelerate CMD research: curecmd.org/2026

Behind every study are researchers working with urgency, care, and a deep commitment to this community.

Want to meet the people behind the science? Watch our Spotlight series on CMD Researchers to hear directly from the scientists pushing this work forward: https://bit.ly/CMDResearcherSpotlight

SELENON: Condition Review, January 2026